poisar

Stock

Serina Therapeutics, Inc. SER

$2.58-3.19%

Overview

SER market data

Price History

SER price chart · 1M
O
2.59
H
2.60
L
2.53
C
2.58
Vol
648.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$2.59
Previous Close
$2.67
Day High
$2.60
Day Low
$2.53
52 Week High
$2.85
52 Week Low
$1.55
7 Day Return
-2.27%
30 Day Return
+24.04%
90 Day Return
+38.71%
1 Year Return
+43.33%
Daily Notional Volume
$1.7K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.88
Diluted earnings per share over the trailing twelve months.
Beta
7.51
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3,498.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.22 – $7.92
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $42.1M · P/B 69.50 · P/S 292.66.

Company News

7 captured
8-K filing — Serina Therapeutics, Inc. (SER)SEC EDGAR · Aug 26, 2026, 10:24 PM
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal InvestmentsBenzinga · Aug 24, 2026, 9:32 PM
Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoYBenzinga · Aug 13, 2026, 8:47 PM
Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s DiseaseBenzinga · Jul 23, 2026, 10:10 AM
Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's DiseaseBenzinga · Jul 9, 2026, 3:50 PM
BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8Benzinga · Jul 1, 2026, 12:00 PM
Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's DiseaseBenzinga · Jun 30, 2026, 1:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock